Goserelin

DB00014

Approved Indication

Used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious pub erty.

2 Targets

0 Resistance Mutations

0 References

3D Structure No structure available

No co-crystal structure available

Protein Targets

GNRHR P30968 ✓ LHCGR P22888 ✓

Mechanism of Action

Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.

Details

DrugBank ID DB00014 ↗

Approval Date 2003-05-05

Molecular Weight 1269.4105 g/mol

Drug Class Other

ATC Codes L02AE03

Synonyms —

PubChem CID: 5311128 ↗

ChEMBL CHEMBL1201247 ↗

SMILES

CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O

ADMET Profile

Computing properties…